A first-class development and manufacturing organization (CDMO), Rottendorf Pharma has been manufacturing, packaging, developing formulations and analytical methods for solid oral dosage forms for the global pharmaceutical industry for more than 85 years. The company produces more than 600 originator and generic drug products annually for big, small, virtual, and global pharmaceutical and biotechnology companies.
Rottendorf operates by the philosophy of Total Process Ownership (TPO) and Total Technological Mastering (TTM), in which we work as an extension of clients’ organizations. Therefore leveraging our expertise to optimize solid dosage form production for our customers benefit. TPO and TTM reduce clients’ management oversight requirements and costs, while improving the supply chain and product quality. As our business strategy, Rottendorf neither have own product brands in the market nor is holding any product licenses, and therefore is never in competition with our clients.
Rottendorf invests in state-of-the-art facilities, featuring best-in-class equipment and technologies, and staffed with over 900 experienced, skilled workers, including many formulation scientists. In our German facilities, compliant with GMP, FDA, ANVISA and others, originator and generic drug products are manufactured, packaged and developed. Clients choose Rottendorf Pharma for our broad-ranging expertise, global regulatory capabilities, commitment to quality, state-of-the-art facilities, and exceptional customer service. As an example, this has been recognized with five CMO Leadership Awards in 2015 for excellence in regulatory, quality, innovation, and productivity.